AMRI re-ups with GE Healthcare, its largest supply partner

Amid budget-slashing and restructuring, AMRI ($AMRI) has some good news to report: The CRO has re-signed with GE Healthcare ($GE) to supply materials for diagnostic imaging, locking down its biggest commercial supply client through 2016.

Under the deal, AMRI will provide aminobisamide hydrochloride through its large-scale manufacturing operation in Rensselaer, NY, extending a contract first inked in 2005.

CEO Thomas D'Ambra said the new deal is an affirmation of AMRI's success in building its large-scale manufacturing arm, headquartered at the Rensselaer facility acquired in 2003. The business grew 14% last quarter, and D'Ambra said AMRI expects it to keep attracting new partners.

"We are adding new customers and new products at this facility, along with continuing the long-term relationships, like GE Healthcare, that have formed the basis of our revenue stream," D'Ambra said in a statement. "The extension of this key, long term-agreement provides a consistent and high-quality revenue source for this business unit through 2016."

Last week, AMRI announced plans to shutter its R&D operation in Bothell, WA, shifting the site's biological capabilities to a Singapore location and absorbing its analytic services into AMRI's Albany, NY, headquarters. The restructuring is aimed to save about $2 million per year, AMRI said, and will result in a one-time charge of $11 million.

AMRI posted 11% in revenue growth last quarter, thanks largely to the boost in large-scale manufacturing sales and an increase in demand for the company's SmartSourcing platform, an all-in-one option for research, development and manufacturing.

- read AMRI's statement

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.